Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2005.055228v2, 2005; 10.1373/clinchem.2005.055228
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.055228v1
clinchem.2005.055228v2
51/11/2067    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holmes, D. T.
Right arrow Articles by Frohlich, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holmes, D. T.
Right arrow Articles by Frohlich, J.

Received on May 30, 2005
Accepted on July 29, 2005

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia

Daniel T. Holmes 1*, Brian A. Schick 1, Karin H. Humphries 2, Jiri Frohlich 1

1 St. Paul's Hospital Lipid Clinic and the University of British Columbia Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada
2 The Centre for Health Evaluations and Outcomes Sciences, St. Paul's Hospital, Vancouver BC, Canada

* To whom correspondence should be addressed. E-mail: dtholmes{at}interchange.ubc.ca.

Background: The role of lipoprotein(a) [Lp(a)] as a predictor of cardiovascular disease (CVD) in patients with heterozygous familial hypercholesterolemia (HFH) is unclear. We sought to examine the utility of this lipoprotein as a predictor of CVD outcomes in the HFH population at our lipid clinic.

Methods: This was a retrospective analysis of clinical and laboratory data from a large multiethnic cohort of HFH patients at a single, large lipid clinic in Vancouver, Canada. Three hundred and eighty-eight patients were diagnosed with possible, probable, or definite HFH by strict clinical diagnostic criteria. Multivariate Cox regression analysis was used to study the relationship between several established CVD risk factors, Lp(a), and the age of first hard CVD event.

Results: An Lp(a) concentration of 800 units/L (560 mg/L) or higher was a significant independent risk factor for CVD outcomes [hazard ratio (HR) = 2.59; 95% confidence interval (CI), 1.53-4.39; P <0.001]. Other significant risk factors were male sex [HR = 3.19 (1.79-5.69); P <0.001] and ratio of total to HDL-cholesterol [1.18 (1.07-1.30); P = 0.001]. A previous history of smoking or hypertension each produced HRs consistent with increased CVD risk [HR = 1.55 (0.92-2.61) and 1.57 (0.90-2.74), respectively], but neither reached statistical significance (both P = 0.10). LDL-cholesterol was not an independent predictor of CVD risk [HR = 0.85 (0.0.71-1.01); P = 0.07], nor was survival affected by the subcategory of HFH diagnosis (i.e., possible vs probable vs definite HFH).

Conclusion: Lp(a) is an independent predictor of CVD risk in a multiethnic HFH population.




The following articles in journals at HighWire Press have cited this article:


Home page
Nephrol Dial TransplantHome page
J. Staples, P. Taylor, A. Magil, J. Frohlich, S. M. Johnston, M. Koschinsky, C. Chan-Yan, and A. Levin
Progressive kidney disease in three sisters with elevated lipoprotein(a)
Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1756 - 1759.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Association for Clinical Chemistry.